251 related articles for article (PubMed ID: 32350988)
41. Analysis of dual energy spectral CT and pathological grading of clear cell renal cell carcinoma (ccRCC).
Wei J; Zhao J; Zhang X; Wang D; Zhang W; Wang Z; Zhou J
PLoS One; 2018; 13(5):e0195699. PubMed ID: 29715308
[TBL] [Abstract][Full Text] [Related]
42. Development of a universal metabolome-standard method for long-term LC-MS metabolome profiling and its application for bladder cancer urine-metabolite-biomarker discovery.
Peng J; Chen YT; Chen CL; Li L
Anal Chem; 2014 Jul; 86(13):6540-7. PubMed ID: 24877652
[TBL] [Abstract][Full Text] [Related]
43. A comprehensive urinary metabolomic approach for identifying kidney cancerr.
Kind T; Tolstikov V; Fiehn O; Weiss RH
Anal Biochem; 2007 Apr; 363(2):185-95. PubMed ID: 17316536
[TBL] [Abstract][Full Text] [Related]
44. CT-based radiomic model predicts high grade of clear cell renal cell carcinoma.
Ding J; Xing Z; Jiang Z; Chen J; Pan L; Qiu J; Xing W
Eur J Radiol; 2018 Jun; 103():51-56. PubMed ID: 29803385
[TBL] [Abstract][Full Text] [Related]
45. Urine aquaporin 1 and perilipin 2 differentiate renal carcinomas from other imaged renal masses and bladder and prostate cancer.
Morrissey JJ; Mobley J; Figenshau RS; Vetter J; Bhayani S; Kharasch ED
Mayo Clin Proc; 2015 Jan; 90(1):35-42. PubMed ID: 25572193
[TBL] [Abstract][Full Text] [Related]
46. RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma.
Liu Y; Cheng G; Song Z; Xu T; Ruan H; Cao Q; Wang K; Bao L; Liu J; Zhou L; Liu D; Yang H; Chen K; Zhang X
Int J Oncol; 2019 Sep; 55(3):645-656. PubMed ID: 31364727
[TBL] [Abstract][Full Text] [Related]
47. LC-MS/MS and SWATH based serum metabolomics enables biomarker discovery in pancreatic cancer.
Xiong Y; Shi C; Zhong F; Liu X; Yang P
Clin Chim Acta; 2020 Jul; 506():214-221. PubMed ID: 32243985
[TBL] [Abstract][Full Text] [Related]
48. Comparison of Biexponential and Monoexponential Model of Diffusion-Weighted Imaging for Distinguishing between Common Renal Cell Carcinoma and Fat Poor Angiomyolipoma.
Ding Y; Zeng M; Rao S; Chen C; Fu C; Zhou J
Korean J Radiol; 2016; 17(6):853-863. PubMed ID: 27833401
[TBL] [Abstract][Full Text] [Related]
49. GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients.
Monteiro M; Moreira N; Pinto J; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Carvalho M; Guedes de Pinho P
J Cell Mol Med; 2017 Sep; 21(9):2092-2105. PubMed ID: 28378454
[TBL] [Abstract][Full Text] [Related]
50. Sensitive Determination of Onco-metabolites of D- and L-2-hydroxyglutarate Enantiomers by Chiral Derivatization Combined with Liquid Chromatography/Mass Spectrometry Analysis.
Cheng QY; Xiong J; Huang W; Ma Q; Ci W; Feng YQ; Yuan BF
Sci Rep; 2015 Oct; 5():15217. PubMed ID: 26458332
[TBL] [Abstract][Full Text] [Related]
51. Non-invasive urine markers for the differentiation between RCCs and oncocytoma.
von Brandenstein M; Herden J; Köditz B; Huerta M; Nestler T; Heidenreich A; Fries JWU
J Clin Lab Anal; 2021 May; 35(5):e23762. PubMed ID: 33960011
[TBL] [Abstract][Full Text] [Related]
52. Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma.
Du Y; Wang Q; Zhang X; Wang X; Qin C; Sheng Z; Yin H; Jiang C; Li J; Xu T
J Exp Clin Cancer Res; 2017 May; 36(1):66. PubMed ID: 28494778
[TBL] [Abstract][Full Text] [Related]
53. MicroRNAs in Serum Exosomes as Potential Biomarkers in Clear-cell Renal Cell Carcinoma.
Zhang W; Ni M; Su Y; Wang H; Zhu S; Zhao A; Li G
Eur Urol Focus; 2018 Apr; 4(3):412-419. PubMed ID: 28753793
[TBL] [Abstract][Full Text] [Related]
54. Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy.
Shang X; Zhong X; Tian X
Tumour Biol; 2016 Aug; 37(8):11163-75. PubMed ID: 26935059
[TBL] [Abstract][Full Text] [Related]
55. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target.
Chen D; Chen W; Xu Y; Zhu M; Xiao Y; Shen Y; Zhu S; Cao C; Xu X
J Med Genet; 2019 Jan; 56(1):43-49. PubMed ID: 29967134
[TBL] [Abstract][Full Text] [Related]
56. Coccidioidomycosis Detection Using Targeted Plasma and Urine Metabolic Profiling.
Jasbi P; Mitchell NM; Shi X; Grys TE; Wei Y; Liu L; Lake DF; Gu H
J Proteome Res; 2019 Jul; 18(7):2791-2802. PubMed ID: 31244214
[TBL] [Abstract][Full Text] [Related]
57. Carbonic anhydrase IX as a specific biomarker for clear cell renal cell carcinoma: comparative study of Western blot and immunohistochemistry and implications for diagnosis.
Giménez-Bachs JM; Salinas-Sánchez AS; Serrano-Oviedo L; Nam-Cha SH; Rubio-Del Campo A; Sánchez-Prieto R
Scand J Urol Nephrol; 2012 Oct; 46(5):358-64. PubMed ID: 22571179
[TBL] [Abstract][Full Text] [Related]
58. Sensitivity and specificity of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 for the diagnosis of renal cell carcinoma.
Morrissey JJ; London AN; Lambert MC; Kharasch ED
Am J Nephrol; 2011; 34(5):391-8. PubMed ID: 21912102
[TBL] [Abstract][Full Text] [Related]
59. Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis.
Xu T; Ruan H; Song Z; Cao Q; Wang K; Bao L; Liu D; Tong J; Yang H; Chen K; Zhang X
Biomed Pharmacother; 2019 Oct; 118():109264. PubMed ID: 31390578
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
